Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totaling 17,195 shares, an increase of 113.0% from the December 15th total of 8,073 shares. Based on an average daily trading volume, of 42,362 shares, the days-to-cover ratio is currently 0.4 days. Currently, 1.0% of the shares of the stock are sold short. Currently, 1.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 42,362 shares, the days-to-cover ratio is currently 0.4 days.

Catheter Precision Stock Up 11.9%

NYSEAMERICAN:VTAK traded up $0.24 during trading hours on Thursday, hitting $2.26. 87,388 shares of the company’s stock traded hands, compared to its average volume of 26,255. Catheter Precision has a 52 week low of $1.49 and a 52 week high of $15.68. The business’s fifty day simple moving average is $2.08 and its two-hundred day simple moving average is $2.74. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.46 and a quick ratio of 0.46.

Catheter Precision (NYSEAMERICAN:VTAK) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($1.70) earnings per share for the quarter, beating the consensus estimate of ($26.60) by $24.90. The firm had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $1.20 million. Catheter Precision had a negative net margin of 2,333.29% and a negative return on equity of 208.54%. On average, equities analysts predict that Catheter Precision will post -8.9 EPS for the current fiscal year.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.